Welcome to the website of
The Blue Ridge Institute for Medical Research (BRIMR)
an independent non-profit organization founded in 2006
This site provides access to two unique BRIMR datasets:
- Authoritative annual rankings of NIH funding to individual researchers and academic institutions; and
- A comprehensive list of the chemical, pharmacological, and clinical characteristics of all protein-kinase inhibitor drugs approved by the FDA.
We are proud to make these data available as resources for the scientific community.
BRIMR is proud to present its 2023 rankings of NIH awards. For a comprehensive analysis of NIH support to institutions, schools, departments, and investigators, we invite you to explore our newly-released BRIMR rankings for the 2023 federal fiscal year, which ended on 30 September 2023. We are grateful to the nearly 100 organizations and individuals whose suggestions during the public comment period helped ensure the accuracy of these results, and to the U.S. National Institutes of Health for its extraordinary support of scientific research and the biomedical enterprise.
Note: The rankings we released on February 6 did not reflect certain corrections, involving 21 awards to 4 organizations, that we had received and approved early in the public-comment period. Those corrections have now been made in revised files posted on February 8 and 19. Most rankings are unaffected except in Family Medicine, Physical Medicine & Rehabilitation, and Schools of Public Health. BRIMR regrets these errors.
Fiscal 2024 is now underway.
Protein Kinase Inhibitors
There are 80 FDA-approved small molecule protein kinase inhibitors as of 29 November 2023. View them here.